【摘要】 阿米替林与安慰剂双盲对照治疗24例神经衰弱,其剂量每日150mg,疗程5wk,以HAMD和SCL-90量表为评定工具。结果表明,治疗组有效率50％,对照组25％,但2组比较差异无显著性(P>0.05)。治疗前后HAMD总分及SCL-90部分因子分变化有显著差异(P<0.05或<0.01),SCL-90总分变化却无统计学差异。看来神经衰弱对阿米替林反应欠佳。更多还原

【Abstract】 Twenty-four neurastheniacs were given amitriptyline or placebo in a double-blind trial. Each patient received a daily dose of 150 mg for 5 wk and their symptoms were assessed with HAMD and SCL-90 (Symptom Check List 90) before and after the treatment. Amitriptyline group showed better clinical effect* (50% improved) than the control group (only 25% improved), but the difference was statistically non-significant. Although the symptoms were improved, P< 0.05 by SCL-90 and HAMD, there was no statistical discrepancy of improvement rates between the two groups.更多还原